NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

細胞療法的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):各類型、治療區分 (自體細胞、同種異體細胞)、地區

Cell Therapy Market Size, Share & Trends Analysis Report By Use-type, By Therapy Type (Autologous, Allogenic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2021 - 2028

出版商 Grand View Research, Inc. 商品編碼 999544
出版日期 內容資訊 英文 120 Pages
商品交期: 2-10個工作天內
價格
細胞療法的市場趨勢、市場佔有率、市場規模的預測 (2021-2028年):各類型、治療區分 (自體細胞、同種異體細胞)、地區 Cell Therapy Market Size, Share & Trends Analysis Report By Use-type, By Therapy Type (Autologous, Allogenic), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2021 - 2028
出版日期: 2021年03月16日內容資訊: 英文 120 Pages
簡介

全球細胞療法的市場規模在預測期間內預計以14.5%的年複合成長率發展,成長到2028年230億美元的規模。

支援先進細胞療法開發的新技術的出現促進該市場的成長。

本報告提供全球細胞療法的市場調查,市場定義和概要,新型冠狀病毒感染疾病 (COVID-19) 以及其他的市場影響因素分析,法律制度,市場規模的變化、預測,類型、治療區分、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

第1章 調查手法、調查範圍

第2章 摘要整理

第3章 市場可變因素、趨勢、展望

  • 市場趨勢、展望
  • 市場分類、範圍
  • 市場動態
  • 普及、成長預測製圖
  • 商業環境分析
  • 法律規範

第4章 COVID-19:影響分析

  • 課題分析
  • 市場機會分析
  • COVID-19的影響
  • 臨床試驗分析
  • 主要市場舉措

第5章 市場分析、預測:各類型

  • 臨床用途
  • 研究用途

第6章 市場分析、預測:各治療種類

  • 同種異體細胞
  • 自體細胞

第7章 市場分析、預測:各地區

  • 市場佔有率成果、預測
  • 市場規模、預測
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第8章 競爭情形

  • 策略性架構
  • 企業簡介
    • Kolon TissueGene, Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • MEDIPOST
    • Smith & Nephew
    • Stemedica Cell Technologies, Inc.
    • Cells for Cells
    • NuVasive, Inc.
    • Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
    • Vericel Corporation
    • PHARMICELL Co., Ltd.
    • ANTEROGEN.CO., LTD
    • Bristol-Myers Squibb Company
目錄
Product Code: GVR-2-68038-701-8

Cell Therapy Market Growth & Trends:

The global cell therapy market size is expected to reach USD 23.0 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 14.5% from 2021 to 2028. The emergence of new technologies to support the development of advanced cellular therapies has aided in market growth. Companies are leveraging new technologies not only for the expansion of their product portfolio but also for establishing out-licensing or co-development agreements with other entities to support their product development programs.

Cell-based therapies hold great potential for replacing, repairing, restoring, or regenerating damaged tissues, and organs. Researchers are making huge investments in the development of such effective and safe treatments as an alternative to conventional treatment strategies which can be further attributed to the market growth. Out of all therapeutic areas, oncology has the highest number of ongoing clinical trials. T cells, CD34+ and/or CD133+ stem cells, mesenchymal stem/stromal cells are predominantly employed for clinical investigation.

The majority of biopharmaceutical entities have been affected by the COVID-19 pandemic, while several cellular therapy development companies have witnessed a strongly negative impact, which can be attributed to complications in logistics as well as the manufacturing models employed in this industry. In addition, substantial and stable funding is imperative to ensure successful commercial translation of cell-based therapeutics, a factor that was negatively affected in 2020, further affecting the market growth.

A survey conducted recently among executives of more than 15 European and U.S. cellular therapy companies indicated that disruption caused by the pandemic was significant, which demanded market entities to create strategies to sustain themselves and plan the next wave of innovative therapies.

Key issues faced by companies operating in the market include on-time delivery of therapies to patients at required clinical sites. In addition, the administration of these therapeutics poses several post-pandemic challenges. Hospitals are hesitant in offering services, owing to concerns over transmission of SARS-CoV-2, particularly to vulnerable individuals. Moreover, patients have not been able to visit cellular therapy centers either, owing to the lockdowns and travel bans.

Cell Therapy Market Report Highlights:

  • The research-use segment dominated the market and accounted for the highest revenue share in 2020 attributed to extensive research activities for developing effective cell and gene therapies
  • Several cells such as neural, epithelial, bone marrow mononuclear, fibroblasts, corneal, antigen-presenting, and chondrocytes, are being explored for the development of novel therapies
  • The clinical-use segment is expected to witness relatively slow growth through the forecast period owing to the limited number of FDA-approved cellular therapies
  • Moreover, there is a withdrawal of several commercialized products and less number of approved products for clinical-use which further affects the growth of the clinical-use segment
  • Based on the therapeutic area, the malignancies segment accounted for the largest revenue share in 2020 owing to the rising application of stem cells in treating various cancers such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma
  • The autologous therapies segment accounted for the largest revenue share in 2020 and it continues the trend through the forecast period owing to the high survival rate associated with this transplant type and relatively high adoption rate
  • The allogenic therapies segment is expected to witness gradual growth through the forecast period owing to the high risk of transplant rejection and high cost associated with allogenic transplants
  • North America has emerged as the highest revenue-generating region in 2020 owing to extensive investments made by the federal bodies for expanding cellular therapy research in the region
  • In Asia Pacific, the market is expected to witness a lucrative growth rate owing to relatively inexpensive manufacturing and operating units, the presence of a large regional population, and untapped potential

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Research Assumptions
  • 1.2 Research Methodology
  • 1.3 Information Procurement
  • 1.4 Information or Data Analysis
  • 1.5 Market Formulation & Validation
  • 1.6 Global Market: CAGR Calculation
  • 1.7 Market Study
    • 1.7.1 Product mapping, By regulatory status
      • 1.7.1.1 Products with RMAT Designations
      • 1.7.1.2 Product study
    • 1.7.2 Market study, by Therapeutic Area
    • 1.7.3 Regional analysis
      • 1.7.3.1 Region-wise market: Base estimates
  • 1.8 Objectives
    • 1.8.1 Objective 1:
    • 1.8.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Cell Therapy Market Variables, Trends, and Scope

  • 3.1 Market Trends and Outlook
  • 3.2 Market Segmentation and Scope
  • 3.3 Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Rise in number of clinical studies for cellular therapies
      • 3.3.1.2 Growing adoption of regenerative medicine
      • 3.3.1.3 Introduction of novel platforms and technologies
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Ethical concerns
      • 3.3.2.2 Clinical issues pertaining to development & implementation of cell therapy
      • 3.3.2.2.1 Manufacturing issues
      • 3.3.2.2.2 Genetic instability
      • 3.3.2.2.3 Condition of stem cell culture
      • 3.3.2.2.4 Stem cell distribution after transplant
      • 3.3.2.2.5 Immunological rejection
      • 3.3.2.2.6 Challenges associated with allogenic mode of transplantation
    • 3.3.3 Market opportunity analysis
      • 3.3.3.1 Approval of Kymriah and Yescarta across various countries
      • 3.3.3.2 Developments in CAR T-cell therapy for solid tumors
      • 3.3.3.3 Technological advancements in manufacturing process
  • 3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2020
  • 3.5 Business Environment Analysis
    • 3.5.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
    • 3.5.2 Porter's Five Forces Analysis
  • 3.6 Regulatory Framework
    • 3.6.1 U.S.
    • 3.6.2 Europe
    • 3.6.3 China
      • 3.6.3.1 Regulatory challenges & risk of selling unapproved cell therapies
    • 3.6.4 Japan

Chapter 4 COVID-19 Impact Analysis

  • 4.1 Challenges analysis
    • 4.1.1 Manufacturing & supply challenges
    • 4.1.2 troubleshooting the manufacturing & supply challenges associated to COVID-19
    • 4.1.3 Other challenges
  • 4.2 Opportunities analysis
    • 4.2.1 Need for development of new therapies against SARS-CoV-2
      • 4.2.1.1 Role of T-cell based therapeutics in COVID-19 management
      • 4.2.1.2 Role of mesenchymal cell-based therapeutics in COVID-19 management
    • 4.2.2 Rise in demand for supply chain management solutions
  • 4.3 Challenges in manufacturing cell therapies against COVID-19
  • 4.4 Clinical Trial Analysis
  • 4.5 Key Market Initiatives

Chapter 5 Cell Therapy Market Categorization: Use Type Estimates & Trend Analysis

  • 5.1 Cell Therapy Market: Use Type Movement Analysis
  • 5.2 Clinical Use
    • 5.2.1 Global cell therapy market for clinical use, 2017 - 2028 (USD Million)
    • 5.2.2 Cell therapy market for clinical use, by therapeutic area
      • 5.2.2.1 Malignancies
      • 5.2.2.1.1 Global cell therapy marketfor malignancies, 2017 - 2028 (USD Million)
      • 5.2.2.2 Musculoskeletal disorders
      • 5.2.2.2.1 Global cell therapy market for musculoskeletal disorders, 2017 - 2028 (USD Million)
      • 5.2.2.3 Autoimmune disorders
      • 5.2.2.3.1 Global cell therapy market for autoimmune disorders, 2017 - 2028 (USD Million)
      • 5.2.2.4 Dermatology
      • 5.2.2.4.1 Global cell therapy market for dermatology, 2017 - 2028 (USD Million)
      • 5.2.2.5 Others
      • 5.2.2.5.1 Global cell therapy marketfor other therapeutic areas, 2017 - 2028 (USD Million)
    • 5.2.3 Cell therapy market for clinical use, by cell type
      • 5.2.3.1 Stem cell therapies
      • 5.2.3.1.1 Global stem cell therapies market, 2017 - 2028 (USD Million)
      • 5.2.3.1.2 Bone marrow, blood, & umbilical cord-derived stem cell therapies
      • 5.2.3.1.2.1 Global bone marrow, blood, & umbilical cord-derived stem cell therapies market, 2017 - 2028 (USD Million)
      • 5.2.3.1.3 Adipose-derived stem cell therapies
      • 5.2.3.1.3.1 Global adipose-derived stem cell therapies market, 2017 - 2028 (USD Million)
      • 5.2.3.1.4 Other stem cell therapies
      • 5.2.3.1.4.1 Global other stem cell therapies market, 2017 - 2028 (USD Million)
      • 5.2.3.2 Non-stem cell therapies
      • 5.2.3.2.1 Global non-stem cell therapies market, 2017 - 2028 (USD Million)
  • 5.3 Research Use
    • 5.3.1 Global cell therapy market for research use, 2017 - 2028 (USD Million)

Chapter 6 Cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis

  • 6.1 Cell Therapy Market: Therapy Type Movement Analysis
  • 6.2 Allogenic Therapies
    • 6.2.1 Global cell therapy market for allogenic therapies, 2017 - 2028 (USD Million)
  • 6.3 Autologous Therapies
    • 6.3.1 Global cell therapy market for autologous therapies, 2017 - 2028 (USD Million)

Chapter 7 Cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Use-type & Therapy Type

  • 7.1 Cell Therapy Market Share by Regional, 2020 & 2028
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
  • 7.5 Latin America
    • 7.5.1 Brazil
  • 7.6 Middle East and Africa (MEA)
    • 7.6.1 South Africa

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Company Profiles
    • 8.2.1 Kolon TissueGene, Inc.
      • 8.2.1.1 Company overview
      • 8.2.1.2 Financial Performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Strategic initiatives
    • 8.2.2 JCR Pharmaceuticals Co., Ltd.
      • 8.2.2.1 Company overview
      • 8.2.2.2 Financial Performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Strategic initiatives
    • 8.2.3 MEDIPOST
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial Performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Strategic initiatives
    • 8.2.4 Smith & Nephew
      • 8.2.4.1 Company overview
      • 8.2.4.2 Osiris Therapeutics, Inc.
      • 8.2.4.2.1 Company Overview
      • 8.2.4.3 Financial Performance
      • 8.2.4.3.1 Financial Performance: Osiris Therapeutics
      • 8.2.4.4 Product benchmarking
      • 8.2.4.5 Strategic initiatives
    • 8.2.5 Stemedica Cell Technologies, Inc.
      • 8.2.5.1 Company overview
      • 8.2.5.2 Financial performance
      • 8.2.5.3 Product benchmarking
      • 8.2.5.4 Strategic initiatives
    • 8.2.6 Cells for Cells
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial Performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.4 Strategic initiatives
    • 8.2.7 NuVasive, Inc.
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial Performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.4 Strategic initiatives
    • 8.2.8 Castle Creek Biosciences, Inc. (Fibrocell Science, Inc.)
      • 8.2.8.1 Company overview
      • 8.2.8.2 Product benchmarking
      • 8.2.8.3 Strategic initiatives
    • 8.2.9 Vericel Corporation
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial Performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Strategic initiatives
    • 8.2.10 PHARMICELL Co., Ltd.
      • 8.2.10.1 Company overview
      • 8.2.10.2 Financial Performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Strategic initiatives
    • 8.2.11 ANTEROGEN.CO., LTD
      • 8.2.11.1 Company overview
      • 8.2.11.2 Financial Performance
      • 8.2.11.3 Product benchmarking
    • 8.2.12 Bristol-Myers Squibb Company
      • 8.2.12.1 Company overview
      • 8.2.12.1.1 Celgene Corporation
      • 8.2.12.2 Financial performance (Bristol-Myers Squibb)
      • 8.2.12.2.1 Financial performance (Celgene Corporation)
      • 8.2.12.3 Product benchmarking
      • 8.2.12.4 Strategic initiatives

List of Tables

  • Table 1 Some approved non-CAR-T cell therapies for clinical-use
  • Table 2 Approved CAR-T cell therapies
  • Table 3 Products with RMAT Designations by the U.S. FDA
  • Table 4 Examples of FDA-approved regenerative medicines
  • Table 5 CAR T-cell resources and potential disruptions during a pandemic
  • Table 6 Ongoing regenerative medicine clinical trials to treat COVID-19 & related complications, as of April 14, 2020
  • Table 7 North America cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 8 North Americacell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 9 North America cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 10 North America stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 11 North America cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 12 U.S. cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 13 U.S. cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 14 U.S. cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 15 U.S. stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 16 U.S. cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 17 Canada cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 18 Canada cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 19 Canada cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 20 Canada stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 21 Canada cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 22 Europe cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 23 Europe cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 24 Europe cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 25 Europe stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 26 Europe cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 27 Germany cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 28 Germany cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 29 Germany cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 30 Germany stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 31 Germany cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 32 U.K.cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 33 U.K.cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 34 U.K.cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 35 U.K.stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 36 U.K.cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 37 Asia Pacific cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 38 Asia Pacific cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 39 Asia Pacific cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 40 Asia Pacific stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 41 Asia Pacific cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 42 Japan cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 43 Japan cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 44 Japan cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 45 Japan stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 46 Japan cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 47 China cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 48 China cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 49 China cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 50 China stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 51 China scell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 52 Latin America cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 53 Latin America cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 54 Latin America cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 55 Latin America stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 56 Latin America cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 57 Brazil cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 58 Brazil cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 59 Brazil cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 60 Brazil stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 61 Brazil cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 62 MEA cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 63 MEA cell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 64 MEA cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 65 MEA stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 66 MEA cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)
  • Table 67 South Africa cell therapy market estimates & forecasts, by use-type, 2017 - 2028 (USD Million)
  • Table 68 South Africacell therapy market for clinical-use estimates & forecasts, by therapeutic area,2017 - 2028 (USD Million)
  • Table 69 South Africa cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 70 South Africa stem cell therapy market for clinical-use estimates & forecasts, by cell-type, 2017 - 2028 (USD Million)
  • Table 71 South Africa cell therapy market estimates & forecasts, by therapy type, 2017 - 2028 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Initiatives by Vericel Corporation to sustain market and boost revenue through its ATMPs
  • Fig. 9 Number of active therapies
  • Fig. 10 Top targets of cell therapies for hematological malignancies, by CAR-T cell therapy type
  • Fig. 11 Top targets of cell therapies for solid tumors, by CAR-T cell therapy type
  • Fig. 12 Factors considered for regional market share analysis
  • Fig. 13 Market summary, 2020 (USD Million)
  • Fig. 14 Market trends & outlook
  • Fig. 15 Market segmentation and scope
  • Fig. 16 Market driver relevance analysis (Current & future impact)
  • Fig. 17 Therapeutic delivery methods investigated in preclinical research in 2017, U.K.
  • Fig. 18 Some future key trends in regenerative medicine
  • Fig. 19 Market restraint relevance analysis (Current & future impact)
  • Fig. 20 Penetration and growth prospect mapping for therapy type, 2020
  • Fig. 21 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • Fig. 22 Porter's Five Forces Analysis
  • Fig. 23 Areas of disruption attributed to the COVID-19 pandemic: Cell therapy manufacturing & delivery
  • Fig. 24 Troubleshooting the challenges associated with COVID-19: Cell therapy development programs
  • Fig. 25 Troubleshooting the challenges associated with COVID-19: Cell therapy manufacturing & delivery
  • Fig. 26 Role of cell-based therapeutics in COVID-19 management
  • Fig. 27 Cell therapy market: Use type outlook key takeaways
  • Fig. 28 Global cell therapy market: Use type movement analysis
  • Fig. 29 Global cell therapy market for clinical use, 2017 - 2028 (USD Million)
  • Fig. 30 Global cell therapy market for malignancies market, 2017 - 2028 (USD Million)
  • Fig. 31 Global cell therapy market for musculoskeletal disorders, 2017 - 2028 (USD Million)
  • Fig. 32 Global cell therapy market for autoimmune disorders, 2017 - 2028 (USD Million)
  • Fig. 33 Global cell therapy market for dermatology, 2017 - 2028 (USD Million)
  • Fig. 34 Global cell therapy market for other therapeutic areas, 2017 - 2028 (USD Million)
  • Fig. 35 Global stem cell therapies market, 2017 - 2028 (USD Million)
  • Fig. 36 Global bone marrow, blood, & umbilical cord-derived stem cell therapies market, 2017 - 2028 (USD Million)
  • Fig. 37 Global adipose-derived stem cell therapies market, 2017 - 2028 (USD Million)
  • Fig. 38 Global other stem cell therapies market, 2017 - 2028 (USD Million)
  • Fig. 39 Global non-stem cell therapies market, 2017 - 2028 (USD Million)
  • Fig. 40 Global cell therapy market for research use, 2017 - 2028 (USD Million)
  • Fig. 41 Cell therapy market: Therapy type outlook key takeaways
  • Fig. 42 Global cell therapy market:Therapy type movement analysis
  • Fig. 43 Global cell therapy market for allogenic therapies, 2017 - 2028 (USD Million)
  • Fig. 44 Global cell therapy market for autologous therapies, 2017 - 2028 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaway
  • Fig. 46 Cell therapy market regional outlook, 2020 & 2028
  • Fig. 47 North America
  • Fig. 48 U.S.
  • Fig. 49 Canada
  • Fig. 50 Europe
  • Fig. 51 Germany
  • Fig. 52 U.K.
  • Fig. 53 Asia Pacific
  • Fig. 54 Japan
  • Fig. 55 China
  • Fig. 56 Latin America
  • Fig. 57 Brazil
  • Fig. 58 Middle East & Africa (MEA)
  • Fig. 59 South Africa
  • Fig. 60 Strategy framework